Growth continues in third quarter for Ipsen
Parisian drugmaker Ipsen (Euronext: IPN) has reported total sales of 727 million euros (846 million) in the third quarter, representing growth of 14.9% from the same period of 2020.
The result was driven by an increase in specialty care sales in the year to date of 12.5%, led by the growth of Somatuline (lanreotide), Cabometyx (cabozantinib), Decapeptyl (triptorelin) and Dysport (abobotulinumtoxinA).
The company also reported strong performance in its consumer healthcare unit, with growth of 9.8% in the year to date, reflecting in part positive uptake for Smecta (diosmectite).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze